GlassScriptPhysician profile
Taylor I Haluck
NPI 1235514977
$2,664.85
in general payments reported to CMS, 2019-2025
26 companies · $705 in 2025
The $705 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $503 · 2023: $505 · 2024: $513 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $797.55 | 2021-2025 | Belbuca, Xtampza |
| Abbvie INC. | $431.83 | 2022-2025 | |
| Abbott Laboratories | $234.06 | 2024-2025 | Eterna, Proclaim |
| Si-Bone, INC. | $154.19 | 2025 | |
| Spr Therapeutics, INC | $117.25 | 2023-2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.53 | 2021-2022 | |
| Almatica Pharma LLC | $81.13 | 2022-2023 | Gralise |
| Grt US Holding, INC. | $72.67 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $64.98 | 2022-2023 | Seglentis |
| Globus Medical, INC. | $61.63 | 2025 | Senza |
| Orexo US, INC. | $60.11 | 2021-2025 | Zubsolv |
| Valinor Pharma, LLC | $60.08 | 2023-2024 | Movantik |
| Hikma Pharmaceuticals USA | $57.45 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $55.01 | 2024-2025 | |
| Allergan, INC. | $50.63 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $49.83 | 2021 | |
| Medtronic, INC. | $43.95 | 2025 | Inceptiv |
| Spinal Simplicity, LLC | $37.15 | 2022 | |
| Scilex Pharmaceuticals INC. | $24.91 | 2022 | |
| Ibsa Pharma INC. | $22.58 | 2022 | |
| Averitas Pharma INC. | $21.21 | 2024 | Qutenza |
| Boston Scientific Corporation | $19.75 | 2023 | |
| Redhill Biopharma INC. | $15.84 | 2021 | |
| Horizon Therapeutics Plc | $15.14 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Haluck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.